FindTrial
Sign In

S095029/Sym025

DRUG2 trials

Sponsors

Institut De Recherches Internationales Servier IRIS

Conditions

MSI-H/dMMR Gastric cancerMSI-H/dMMR Gastroesophageal-junction CancerNon-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiationor - Metastatic NSCLC

Phase 1

Open label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastro-esophageal junction/gastric cancer
Active, not recruitingCTIS2023-507995-33-00
Institut De Recherches Internationales Servier IRISMSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
Start: 2024-05-23Target: 31Updated: 2026-01-19
A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression
RecruitingCTIS2023-508730-34-00
Institut De Recherches Internationales Servier IRISNon-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC
Start: 2024-07-10Target: 93Updated: 2025-12-24